Docket No.: 104385.145US1

PATENT/OFFICIAL A

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

h re Application of

Guiyi ZHANG-SUN et al.

Serial No. 10/075,542 Group Art Unit: 1651

Filed: February 15, 2002 Examiner: David M. Naff

MATRIX STABILIZED ENZYME CRYSTALS AND METHODS OF USE

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

In accordance with 37 C.F.R. § 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search had been made or that information cited is, or is considered to be, material to patentability as defined in 37 C.F.R.§ 1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item, and Applicant reserves the right to prove that the date of publication is in fact different.

Copies of the documents listed on page 1 of Form PTO-1449, some of which were cited in the prosecution of the corresponding PCT patent application, are enclosed. A copy of the search report for the PCT patent application is also enclosed.

11/07/2003 CNGUYEN 00000089 080219 10075542

01 FC:1806

180.00 DA

The Commissioner is authorized to charge the fee of \$180.00 pursuant to 37 CFR § 1.17(p) and is attached any deficiency in any fees pursuant to 37 CFR § 1.17 associated with this communication and to credit any excess payment to Deposit Account No. 08-0219.

Respectfully submitted,

HALE AND DORR LLP

Registration No. 42,967

1455 Pennsylvania Avenue, NW

Washington, DC 20004

202.942.8400 MLM/mgm

FAX 202.942.8484 Date: 6 November 2003

OIPE	
MOA 0 6 5003	OFFICE
PRADEMAR	

INFORMATION DISCLOSURE CITATION IN AN

ATTY. DOCKET NO. 104385.145US1

SERIAL NO. 10/075,542

SHEET 1 OF 1

(PTO-1449)

**APPLICATION** 

APPLICANT

Guiyi ZHANG-SUN et al.

FILING DATE February 15, 2002

GROUP 1651

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS		ING ATE	
	4,970,156	11/13/90	Avrameas et al.			09/13	/85	
	5,618,710	04/08/97	Navia et al.			02/12	2/93	
					<u></u>	_		
<del></del>				-		-		
		<del></del>						
			· · · · · · · · · · · · · · · · · · ·					
						<u> </u>		
		FO	REIGN PATENT DOCUMENT	'S				
EXAMINER'S INITIALS	PATENT NO. DA	DATE	COUNTRY	CLASS	SUBCLASS	Translation		
		DAIL	COONIKI	CLASS		Yes	No	
	WO 95/00171	01/05/95	WO			X		
	EP 0 861 888	09/02/98	EP			Х		
	and the street of the street o	eare equitions. It is the	uding Author, Title, Date, Perti					
		om Proteolytic	er 26, 1986. "Entrapment of Pher Attack." Biochemical and Bioph					
	Chang, Thomas Ming Swi. 1998. "Pharmaceutical and therapeutic applications of artificial cells including microencapsulation." European Journal of Pharmaceutics and Biopharmaceutics, Vol. 45, No.1. pp. 3 – 8							
			arch Report from PCT/IB02/0190					
EXAMINER		DATE CONSIDERED						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.